Trials / Completed
CompletedNCT00134511
Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder
Phase 3 Multi-Center, Open Label, Forced Titration Study To Evaluate The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Combination Administered Orally, Once Daily (Qd) In Patients With Homozygous Familial Hypercholesterolaemia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 30 (planned)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To evaluate the efficacy and safety of the lipid drug Torcetrapib/atorvastatin in patients with genetically known disorder of extremely high cholesterol
Detailed description
For additional information please call: 1-800-718-1021
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Torcetrapib/atorvastatin |
Timeline
- Start date
- 2005-03-01
- Completion
- 2005-11-01
- First posted
- 2005-08-24
- Last updated
- 2007-11-07
Locations
6 sites across 3 countries: United States, Canada, South Africa
Source: ClinicalTrials.gov record NCT00134511. Inclusion in this directory is not an endorsement.